Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1627 1629
This examiner grants 100% of resolved cases
Pauline Wanjiku Much Ondachi is an examiner in Art Unit 1627 of Tech Center 1600. Based on a single resolved case, she has a 100.0% allowance rate and an interview lift of 0.0%. The median time to allowance for this case was 1012 days.
While the 100.0% rate is based on limited data, it provides an initial benchmark for her prosecution style. The 0.0% lift indicates that the single grant was achieved without the statistical impact of an interview. Practitioners should note the 1012-day pendency as the current timeline for her work.
The 100.0% allowance rate is a favorable start for this examiner. As more of the 1 cases are resolved, the 1012-day median and 0.0% lift may shift. For now, the data suggests a successful path in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18569149 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | Non-Final OA | LG CHEM, LTD. |
| 18712594 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | Non-Final OA | The Regents of the University of California |
| 18720994 | FUNGICIDAL COMPOSITIONS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18705175 | TOLL-LIKE RECEPTOR AGONISTS AND ANTAGONISTS AND USES THEREOF | Non-Final OA | Regents of the University of Minnesota |
| 18676514 | CHIRAL AMINE-SQUARAMIDE COMPOUND BASED ON SPIROBIINDANE SKELETON, PREPARATION METHOD AND USE THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18542910 | PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | Final Rejection | Boehringer Ingelheim International GmbH |
| 18562019 | ACID DIANHYDRIDE | Non-Final OA | MITSUBISHI GAS CHEMICAL COMPANY, INC. |
| 18704872 | CERTAIN N-(1-CYAN0-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS | Non-Final OA | Insmed Incorporated |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy